Lilly started phase 3 testing of LY-CoV555 to prevent COVID-19. The BLAZE-2 study will be conducted jointly with the National Institute of Allergy and Infectious Diseases. It will involve about 2400 residents and staff of nursing homes where coronavirus has been detected and there is a high risk of infection.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept